OncoSil Medical Receives FDA Exemption Approval for Targeted Radiation Device
· smallcaps.com.au
OncoSil wins FDA humanitarian device exemption for dCCA, unlocking US market ~1,000 patients/year and $80m TAM; launch set for H2 2027.
OncoSil Medical (ASX: OSL) has received humanitarian device exemption (HDE) approval from the US Food and Drug Administration (FDA) for its OncoSil device to tr...